TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.0100nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.0100nMAssay Description:Non-limiting examples of the HPTP-β IC50 (μM) activity.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.0100nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.0100nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.0800nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.0800nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.0800nMAssay Description:Non-limiting examples of the HPTP-β IC50 (μM) activity.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.0800nMAssay Description:Non-limiting examples of the HPTP-β IC50 (μM) activity.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.0800nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.0800nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.0800nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.0800nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.0900nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.0900nMAssay Description:Non-limiting examples of the HPTP-β IC50 (μM) activity.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.0900nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.0900nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.100nMAssay Description:Non-limiting examples of the HPTP-β IC50 (μM) activity.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.100nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.100nMAssay Description:Non-limiting examples of the HPTP-β IC50 (μM) activity.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.100nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.100nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.100nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.100nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.100nMAssay Description:Non-limiting examples of the HPTP-β IC50 (μM) activity.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.100nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.100nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.100nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.100nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.140nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.140nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.140nMAssay Description:Non-limiting examples of the HPTP-β IC50 (μM) activity.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.140nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.157nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.157nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.157nMAssay Description:Non-limiting examples of the HPTP-β IC50 (μM) activity.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.157nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.162nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.162nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.162nMAssay Description:Non-limiting examples of the HPTP-β IC50 (μM) activity.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.162nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.200nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.200nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.200nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.200nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.200nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.200nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.200nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.200nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.200nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.200nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair